NEW YORK (GenomeWeb News) – Beckman Coulter Genomics, the genomics services subsidiary of Beckman Coulter, today said that it is teaming up with Genpathway to offer customers whole-genome chromatin immunoprecipitation sequencing (ChIP-Seq) services.
ChIP-Seq combines chromatin immunoprecipitation with ultra high-throughput next-generation DNA sequencing, enabling researchers to study complex interactions between proteins and nucleic acids. The services that the firms will offer will include ChIP experimental design and consultation, antibody qualification, performance of ChIP assays with post-ChIP QC, next-generation sequencing, and comprehensive data analysis, according to Danvers, Mass.-based Beckman Coulter Genomics.
"This dynamic new alliance is a natural fit, coupling Beckman Coulter Genomics' sequencing and marketing capabilities with Genpathway's ChIP experience to offer the global research community an expert source of ChIP sequencing data and analysis," Patrick Mallon, CEO of San Diego-based Genpathway, said in a statement.
Among Beckman Coulter Genomics' services are Sanger and next-gen sequencing, gene expression profiling, genotyping, and biologics testing.